<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04138901</url>
  </required_header>
  <id_info>
    <org_study_id>HS-2019-01</org_study_id>
    <nct_id>NCT04138901</nct_id>
  </id_info>
  <brief_title>Postoperative Analgesic Effect of Subcostal TAPB for Laparoscopic Gastrectomy</brief_title>
  <official_title>Postoperative Analgesic Effect of Ultrasound Guided Subcostal Transversus Abdominis Plane Block in Gastric Cancer Patients Undergoing Laparoscopic Gastrectomy: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized, single blinded study is designed to evaluate the postoperative
      analgesic efficacy of the ultrasound-guided subcostal transversus abdominis plane block in
      gastric cancer patients undergoing laparoscopic gastrectomy. We hypothesize that US guided
      subcostal TAP block with ropivacaine can significantly reduce postoperative opioid comparison
      in patients with laparoscopic gastrectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients undergoing elective laparoscopic gastrectomy are randomly allocated to receive
      subcostal TAP block (n=55) or not, in addition to a standard postoperative analgesic regimen
      comprising of IV fentanyl-based patient-controlled analgesia (PCA) and NSAIDs as required. At
      the end of surgery, the TAP group patients will receive bilateral subcostal TAP block under
      ultrasound guidance with 15ml of 0.375% ropivacaine bilaterally. Each patient was assessed by
      a blinded investigator at 12, 24, and 48 h postoperatively. The primary outcome is total
      fentanyl consumption at 24 h after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2019</start_date>
  <completion_date type="Anticipated">August 30, 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A prospective randomized double-blinded study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>We plan to perform TAPB in patients under general anesthesia. Physicians not involved in this study will investigate the outcomes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total fentanyl consumption during 24 hours</measure>
    <time_frame>postoperative 24 hours</time_frame>
    <description>postoperative fentanyl consumption (mcg) via IV patient controlled analgesia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total fentanyl consumption</measure>
    <time_frame>postoperative 12, 48 hours</time_frame>
    <description>postoperative fentanyl consumption (mcg) via IV patient controlled analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain score</measure>
    <time_frame>postoperative 12, 24, 48 hours</time_frame>
    <description>11-pointed NRS pain score at resting/coughing/movement NRS (0-10): 0, &quot;no pain&quot;; 10, &quot;worst pain imaginable&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>postoperative 12, 24, 48 hours</time_frame>
    <description>Incidence of postoperative nausea and vomiting (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction for postoperative pain management</measure>
    <time_frame>postoperative 24, 48 hours</time_frame>
    <description>7-pointed likert scale (very satisfied-somewhat satisfied-satisfied-neutral-dissatisfied-somewhat dissatisfied-very dissatisfied)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue opioid/nonopioid(ketorolac) analgesic requirement</measure>
    <time_frame>postoperative 12, 24, 48 hours</time_frame>
    <description>Overall postoperative rescue of opioid/nonopoioid(ketorolac) analgesic requirement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving bilateral subcostal TAP block.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients not receiving bilateral subcostal TAP block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ultrasound guided subcostal transversus abdominis plane block (TAPB)</intervention_name>
    <description>At the end of surgery, an anesthesiologist will perform bilateral subcostal TAP block with 0.375% ropivacaine 15ml at each site under ultrasound guidance.</description>
    <arm_group_label>Group T</arm_group_label>
    <other_name>TAP block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.75% Injectable Solution</intervention_name>
    <description>0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)</description>
    <arm_group_label>Group T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)</intervention_name>
    <description>0.375% ropivacaine is injected to the transversus abdominis plane via 21G 100 mm stimulator needle (Echoplex®, Vygon, Ecouen, France)</description>
    <arm_group_label>Group T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to undergo elective laparoscopic gastrectomy under general
             anesthesia

          -  American Society of Anesthesiologists (ASA) physical classification I-III

          -  Consent to IV-patient controlled analgesia use

          -  Willingness and ability to sign an informed consent document

        Exclusion Criteria:

          -  Do not understand our study

          -  Allergies to anesthetic or analgesic medications

          -  Wound infiltration analgesia for postoperative pain control

          -  Infection or anatomic abnormality at the needle insertion site

          -  Pregnancy/Breast feeder

          -  Medical or psychological disease that can affect the treatment response
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hojin Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hojin Lee, MD</last_name>
    <phone>82-2-2072-2467</phone>
    <email>zenerdiode03@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susie Yoon, MD</last_name>
    <phone>82-2-2072-2467</phone>
    <email>susie87@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>KS013</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hojin Lee, MD</last_name>
      <phone>82-2-2072-2467</phone>
      <email>zenerdiode03@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Susie Yoon, MD</last_name>
      <phone>82-2-2072-2467</phone>
      <email>susie87@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 23, 2019</study_first_submitted>
  <study_first_submitted_qc>October 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2019</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hojin Lee, MD</investigator_full_name>
    <investigator_title>Clinical assistant professor</investigator_title>
  </responsible_party>
  <keyword>Postoperative pain</keyword>
  <keyword>Stomach neoplasms</keyword>
  <keyword>Nerve block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

